Ajanta Pharma has reported results for second quarter ended September 30, 2013.
The company has reported over two and a half fold jump in its net profit at Rs 55.81 crore for the quarter as compared to Rs 21.88 crore for the same quarter in the previous year. Total income from operation of the company has increased by 50.15% at Rs 279.83 crore for quarter under review as compared to Rs 186.37 crore for the quarter ended September 30, 2012.
Ajanta Pharma is engaged manufacturing pharmaceutical products. The company runs three divisions -- prescription drugs, OTC and institutional sales.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: